NCT03543306

Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation

An Open-label, Multicenter, Phase II Study of Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 27 (estimated)
• Sponsor: Asan Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase II, non-randomized, open-label study to assess the efficacy, safety, and tolerability of dabrafenib and trametinib in stage IV disease to subjects with BRAF V600E mutant advanced non-small cell lung cancer. Subjects will receive dabrafenib 150 mg bid and trametinib 2 mg once daily in combination therapy and continue on treatment until disease progression, death, or unacceptable adverse event.

Conditions

• Cancer
• Lung Cancer Metastatic
• BRAF V600E

Interventions

Type	Name	Description
DRUG	daborafenib plus trametinib	Dabrafenib 150 mg twice daily and trametinib 2 mg once daily

Timeline

• Start date: 2018-06-30
• Primary completion: 2020-06-30
• Completion: 2022-06-30
• First posted: 2018-06-01
• Last updated: 2018-06-01

Locations

1 site across 1 country: South Korea